Table 5.
Patient characteristics associated with PDIs (simultaneous long-term and potential high-risk use) in Q2 2019
| Variable (no. of patients)d | Odds ratio (95% CI) crude | Odds ratio (95% CI) adjusteda |
|---|---|---|
| Sex | ||
| Men (n = 23,633) | Reference | Reference |
| Women (n = 48,428) | 1.17 (1.14–1.21) | 1.07 (1.02–1.11) |
| Age groups | ||
| 18–39 (n = 17,390) | Reference | Reference |
| 40–64 (n = 35,587) | 2.82 (2.67–2.97) | 2.17 (2.03–2.31) |
| 65–79 (n = 13,453) | 9.51 (8.99–10.05) | 14.12 (13.15–15.17) |
| 80–100 (n = 5631) | 8.42 (7.88–8.98) | 12.26 (11.23–13.37) |
| Total no. of drugs dispensed Q2 2019 | ||
| 1 to 4 drugs (n = 34,165) | Reference | Reference |
| 5 to 9 drugs (n = 24,322) | 4.53 (4.35–4.71) | 3.43 (3.27–3.59) |
| 10 to 14 drugs (n = 10,251) | 8.17 (7.80–8.56) | 5.24 (4.94–5.57) |
| ≥ 15 drugs (n = 3323) | 12.72 (11.87–13.63) | 7.37 (6.71–8.10) |
| Antidepressant agentb | ||
| SSRI (n = 42,057) only | Reference | Reference |
| SNRI (n = 6518) only | 1.25 (1.18–1.32) | 0.95 (0.89–1.02) |
| TCA (≥ 50 mg) (n = 3388) only | 7.04 (6.53–7.58) | 5.49 (5.02–6.01) |
| Mirtazapine (low dose) (n = 3289) only | 0.66 (0.60–0.72) | 0.23 (0.21–0.26) |
| NASSA (high dose) (n = 5849) only | 0.78 (0.73–0.84) | 0.40 (0.37–0.43) |
| Other AD (n = 1824) only | 0.90 (0.81–1.01) | 0.39 (0.34–0.44) |
| Combined use of ≥ 2 ADs (n = 9136) | 6.29 (6.00–6.59) | 5.52 (5.20–5.85) |
| Residencec | ||
| Large urban area (n = 17,336) | Reference | Reference |
| Urban area (n = 33,674) | 0.95 (0.91–0.98) | 0.90 (0.86–0.95) |
| Accessible rural area (n = 18,718) | 0.93 (0.89–0.97) | 0.86 (0.81–0.90) |
| Remote rural area (n = 2333) | 1.01 (0.93–1.10) | 0.85 (0.76–0.95) |
aAdjusted for all variables shown in the table
bThe list includes all antidepressants with potential deprescribing indications identified by the indicators (TCA < 50 mg only does not trigger any indicator)
cScottish Executive Urban–Rural Classification
dNumber of patients included in the multivariate analysis